Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Abiad Visits the Karantina Warehouse and Public Hospital with a Delegation from the Republic of Korea and UNICEF

 
Following the announcement of new contribution from the Republic of Korea to ensure new-borns’ lifesaving care across selected governmental hospitals and the availability of essential paediatric acute medications in primary healthcare centres, the minister of public health held a joint field visit to the Karantina warehouse and hospital with Korean Ambassador to Lebanon and UNICEF Representative. 

The new funding will ensure the access of vulnerable populations to essential medications at primary healthcare centres and intensive lifesaving care services in public hospitals to avoid any supply rupture and allow timely access to acute treatments for children and mothers.  

The Minister of Public Health, Dr. Firass Abiad, indicated that "this donation will contribute to supporting the most vulnerable". He pointed out that "this is not the first time that the Republic of Korea  and UNICEF have stood by Lebanon.  through cooperation with partners, the Ministry of Public Health, in light of the difficult economic and political circumstances in Lebanon and the fact that Lebanon is hosting large numbers of displaced people, is trying to fulfill its duties towards everyone by providing health services and medicine in Primary health care centers".

Ambassador of the Republic of Korea in Lebanon, Mr.  Il Park said: “Korea recognizes the importance of providing essential healthcare services to the most vulnerable members of society, particularly children and newborns. We firmly believe that every child deserves the right to receive proper medical attention and care, regardless of their circumstances.”

The procured acute medications includes antibiotics, and anti-inflammatories allow to fill the gap in the acute medication supply induced by high demand for care from the most vulnerable children in Lebanon. Supporting vulnerable families to cover the out of pocket payment for their infants and children intensive care services helps eliminate the financial barrier to accessing lifesaving care. 

Edouard Beigbeder, UNICEF Representative in Lebanon, emphasized the organization's dedication to bridging vital healthcare access disparities and maintaining life-saving assistance for mothers and children in Lebanon. “Thanks to the ongoing generous support from the Republic of Korea, we can broaden our initiatives to encompass more vulnerable areas and additional hospitals, with a particular focus on enhancing support in Baalbek and Akkar."
    3
    ...
ATC Name B/G Ingredients Dosage Form Price
J05AR03 EMZAVIR G Emtricitabine - 200mg, Tenofovir disoproxil fumarate - 300mg Tablet, film coated 18,701,506 L.L
C09BB06 ENEAS G Enalapril maleate - 10mg, Nitrendipine - 20mg Tablet 2,009,045 L.L
B01AB05 ENOXAMED BioTech Enoxaparin sodium - 10000IU Anti-XA/1ml 10000IU Anti-XA/1ml Injectable solution 1,209,458 L.L
B01AB05 ENOXA MEDIS BioTech Enoxaparin sodium - 2,000U Anti-Xa/0.2ml 2,000U Anti-Xa/0.2ml Injectable solution 388,370 L.L
B01AB05 ENOXAMED BioTech Enoxaparin sodium - 2000IU Anti-XA/0.2ml 2000IU Anti-XA/0.2ml Injectable solution 1,105,982 L.L
B01AB05 ENOXAMED BioTech Enoxaparin sodium - 2000IU Anti-XA/0.2ml 2000IU Anti-XA/0.2ml Injectable solution 388,370 L.L
B01AB05 ENOMEX BioTech Enoxaparin sodium - 2000U Anti-Xa/0.2ml 2000U Anti-Xa/0.2ml Injectable solution 396,754 L.L
B01AB05 ENOXA MEDIS BioTech Enoxaparin sodium - 4,000U Anti-Xa/0.4ml 4,000U Anti-Xa/0.4ml Injectable solution 755,239 L.L
B01AB05 ENOXAMED BioTech Enoxaparin sodium - 4000IU Anti-XA/0.4ml 4000IU Anti-XA/0.4ml Injectable solution 755,239 L.L
B01AB05 ENOXAMED BioTech Enoxaparin sodium - 4000IU Anti-XA/0.4ml 4000IU Anti-XA/0.4ml Injectable solution 2,150,148 L.L
B01AB05 ENOMEX BioTech Enoxaparin sodium - 4000U Anti-Xa/0.4ml 4000U Anti-Xa/0.4ml Injectable solution 753,832 L.L
B01AB05 ENOXAPARIN LEDRAXEN BioTech Enoxaparin sodium - 4000UI (40mg)/0.4ml 4000UI (40mg)/0.4ml Injectable solution 841,245 L.L
B01AB05 ENOXA MEDIS BioTech Enoxaparin sodium - 6,000U Anti-Xa/0.6ml 6,000U Anti-Xa/0.6ml Injectable solution 765,990 L.L
B01AB05 ENOXAMED BioTech Enoxaparin sodium - 6000IU Anti-XA/0.6ml 6000IU Anti-XA/0.6ml Injectable solution 765,990 L.L
B01AB05 ENOXAMED BioTech Enoxaparin sodium - 6000IU Anti-XA/0.6ml 6000IU Anti-XA/0.6ml Injectable solution 3,637,782 L.L
B01AB05 ENOMEX BioTech Enoxaparin sodium - 6000U Anti-Xa/0.6ml 6000U Anti-Xa/0.6ml Injectable solution 922,772 L.L
B01AB05 ENOXAPARIN LEDRAXEN BioTech Enoxaparin sodium - 6000UI (60mg)/0.6ml 6000UI (60mg)/0.6ml Injectable solution 854,684 L.L
B01AB05 ENOXA MEDIS BioTech Enoxaparin sodium - 8,000U Anti-Xa/0.8ml 8,000U Anti-Xa/0.8ml Injectable solution 963,535 L.L
B01AB05 ENOXAMED BioTech Enoxaparin sodium - 8000IU Anti-XA/0.8ml 8000IU Anti-XA/0.8ml Injectable solution 963,535 L.L
B01AB05 ENOXAMED BioTech Enoxaparin sodium - 8000IU Anti-XA/0.8ml 8000IU Anti-XA/0.8ml Injectable solution 4,575,784 L.L
B01AB05 ENOMEX BioTech Enoxaparin sodium - 8000U Anti-Xa/0.8ml 8000U Anti-Xa/0.8ml Injectable solution 1,025,160 L.L
J05AF10 ENTECAVIR ARROW G Entecavir - 0.5mg 0.5mg Tablet, coated 18,701,506 L.L
J05AF10 ENTECAVIR BIOGARAN G Entecavir - 0.5mg 0.5mg Tablet, coated 19,080,319 L.L
J05AF10 ENTRILIV G Entecavir - 0.5mg 0.5mg Tablet, film coated 19,165,898 L.L
J05AF10 ENTECAVIR ARROW G Entecavir - 0.5mg 0.5mg Tablet, coated L.L
J05AF10 ENTECAVIR ARROW G Entecavir - 1mg 1mg Tablet, coated 18,701,506 L.L
J05AF10 ENTECAVIR BIOGARAN G Entecavir - 1mg 1mg Tablet, coated 19,080,319 L.L
J05AF10 ENTRILIV G Entecavir - 1mg 1mg Tablet, film coated 19,165,898 L.L
J05AF10 ENTECAVIR ARROW G Entecavir - 1mg 1mg Tablet, coated L.L
L02BB04 ENZASTIK 40 G Enzalutamide - 40mg 40mg Capsule 82,838,963 L.L
    3
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025